Monash University

New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center

Retrieved on: 
Freitag, Mai 3, 2024
News, Pediatrics, Surgeon, Doctor of Philosophy, Bachelor of Science, Baylor University, Diagnosis, Texas Children's Hospital, Medical director, University, DRS, Ventricular septal defect, Baylor College of Medicine, Faculty, Moss, Royal Children, National university, Royal college, Executive, Hospital, Research, Monash University, Division, Congenital heart defect, Arrhythmia, Cardiomyopathy, NHS foundation trust, Evelina London Children's Hospital, Patient, Principal, Molecular medicine, Growth, Dentistry

Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.

Key Points: 
  • Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.
  • "We are incredibly proud to announce our new Heart Center executive leadership team," said Dr. Lara Shekerdemian , Pediatrician-In-Chief and chair of Pediatrics at Texas Children's Hospital.
  • "I am truly honored to join the leadership team at Texas Children's Heart Center," said Dr. Salih.
  • "For many decades now, Texas Children's Heart Center has cared for the world's rarest and most complex heart conditions.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Dienstag, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

Online schooling is not just for lockdowns. Could it work for your child?

Retrieved on: 
Donnerstag, April 18, 2024
Online, Research, Capital districts and territories, Health, Territory, Learning, Science, Internet access, School, Mental health, History, Child, Social isolation, Student, Meditation, Monash University, Atmosphere of Earth, Nursing, Social, Parent, Catholic Church, Tutoring

During COVID almost all Australian students and their families experienced online learning. But while schools have long since gone back to in-person teaching, online learning has not gone away. What are online schools doing now? What does the research say? And how do you know if they might be a good fit for your child? Online learning in AustraliaWhile learning in COVID lockdowns was extremely tough, it also showed schools, students and parents the potential benefits of online learning for a wider range of students.

Key Points: 


During COVID almost all Australian students and their families experienced online learning. But while schools have long since gone back to in-person teaching, online learning has not gone away. What are online schools doing now? What does the research say? And how do you know if they might be a good fit for your child?

Online learning in Australia

  • While learning in COVID lockdowns was extremely tough, it also showed schools, students and parents the potential benefits of online learning for a wider range of students.
  • This can include greater accessibility (learning from any location) and flexibility (personalised, self-paced learning).
  • This has prompted an expansion of online learning options in Australia.

Primary and high school options

  • For example, Monash University has a free virtual school with revision sessions for Year 12 students.
  • Read more:
    Australia has a new online-only private school: what are the options if the mainstream system doesn't suit your child?

What about academic outcomes?

  • Research on the academic outcomes of distance education students is inconclusive.
  • A 2017 study of primary and high school students in Ohio found reduced academic progress in reading, maths, history and science.
  • Another 2017 US study also found online students had lower graduation rates than their in-person peers.

What about wellbeing?

  • This includes access to specialists such as psychologists, nurses and social workers.
  • Some research has noted concerns about online student engagement, social isolation, sense of belonging and social and emotional development.

Is online learning a good fit for your child?

  • However, if certain subjects are unavailable, or health, elite sport and distance to school make in-person learning difficult, learning online could be a viable option to consider.
  • Because online learning tends to be a mix of live lessons and self-paced learning, online students need to be independent, motivated and organised to succeed.


Brendon Hyndman is Senior Manager - Research, Innovation and Impact with Brisbane Catholic Education. Vaughan Cruickshank does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Retrieved on: 
Dienstag, April 9, 2024
Disability, Cardiovascular disease, Myocardial infarction, CVD, Risk, Patient, Stroke, NAMS, History, Mortality, Death, FESC, Moyamoya disease, Phase 3, Monash University, MACE, ASCVD, Hypercholesterolemia, Pharmaceutical industry

Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.

Key Points: 
  • Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.
  • “PREVAIL, our pivotal CVOT, will potentially demonstrate that obicetrapib’s lowering of LDL-C will reduce major adverse cardiac events (“MACE”).
  • The primary objective of the study is to evaluate the effect of obicetrapib compared to placebo on MACE, including cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization.
  • “Despite widespread availability of statin therapies, CVD-related deaths are on the rise, and many patients are not at their risk-based LDL-C goals.

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Montag, April 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Retrieved on: 
Dienstag, Februar 20, 2024
Infection, Bangladesh Technical Education Board, Fungus, Hospital, Candida auris, NIAID, NIH, Marketing, FDA, Food, Tafenoquine, Risk, Malaria, Patient, Monash University, Oxidative stress, Ageing, Research, Fungal infection, Pharmaceutical industry

C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.

Key Points: 
  • C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.
  • The study will be conducted by Monash University in Melbourne, Australia, beginning in the second quarter of 2024.
  • “The rapid transmission of Candida auris in healthcare facilities is a very real threat and the need for a safe, effective treatment option is becoming more urgent every day,” said 60 Degrees Pharmaceuticals Chief Executive Officer and President, Geoff Dow.
  • Like other 8-aminoquinoline antimalarials, tafenoquine is expected to kill fungi by disrupting cellular responses to oxidative stress, differentiating it from other antifungals.

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

Retrieved on: 
Dienstag, Februar 20, 2024
Health, Medical Devices, Surgery, Health Technology, General Health, Clinical Trials, Cardiology, The Alfred Hospital, USD, Multimedia, University of Queensland, The Texas Heart Institute, University, FDA, Cancer, Hospital, IDE, Artificial heart, Griffith University, Heart failure, MRFF, Fatigue, TAH, Patient, Monash University, Survival, Periodic breathing, EFS, Pharmaceutical industry

BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

Key Points: 
  • BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
  • View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
    BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
    Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR.
  • The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
  • “There is a huge gap between available treatment options and the number of patients with severe heart failure.

Korean Government Delegation and KACES Conclude Successful 3rd UNESCO World Conference on Culture and Art Education

Retrieved on: 
Montag, Februar 19, 2024
Primary, Secondary, Arts, Museums, Education, Entertainment, Music, Other Education, University, UNESCO, Ministry, Sir, Multimedia, Professor, Value, Access, Group Policy, Yonsei University, Multilateralism, Conference, Digital technology, MSCT, School, MCST, Policy, Monash University, Sport, Elected, UN, Hansung University, Speech, Management

The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.

Key Points: 
  • The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.
  • View the full release here: https://www.businesswire.com/news/home/20240219103477/en/
    The 3rd UNESCO World Conference on Culture and Arts Education is held in Abu Dhabi, United Arab Emirates (Photo: KOREA ARTS & CULTURE EDUCATION SERVICE)
    Held for the first time since 2010's Seoul event, the 3rd UNESCO World Conference on Culture and Arts Education aimed to reflect evolving social values and adopt the revised Framework for Culture and Arts Education.
  • During the first session, MCST's Culture and Arts Policy Director, Lee Hae-don, gave a presentation titled "A Fair Opportunity for Access to Culture and Arts Education."
  • A MCST official said, “In this conference, which was aimed at discussing the directivity of global culture and arts education, Korea’s leadership in the field of culture and arts education was demonstrated.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240219103477/en/

Titan Machinery Elects New Board Member

Retrieved on: 
Donnerstag, Januar 18, 2024
Titan, Region, Chairperson, Employment, Mining, Business, Executive, Caterpillar Inc., Titan Machinery, Acquisition, Monash University, Marketing, Tractor, Caterpillar, Film industry

WEST FARGO, N.D., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (NASDAQ:TITN) announced today that it has elected Richard E. Lewis to its Board of Directors.

Key Points: 
  • WEST FARGO, N.D., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (NASDAQ:TITN) announced today that it has elected Richard E. Lewis to its Board of Directors.
  • With the election of Mr. Lewis, the Board will consist of nine directors, including seven independent directors.
  • “We are pleased that Richard has accepted the invitation to join our Board of Directors,” said David Meyer, Titan Machinery’s Board Chair and CEO.
  • We believe that Titan Machinery and our Board will benefit from Richard’s valuable and unique business experience.”
    Mr. Lewis currently serves as director and the principal executive of Iron Capital Group, a company founded by Mr. Lewis in 2015.

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Retrieved on: 
Donnerstag, Januar 18, 2024
Data monitoring committee, Patient, Research, Clutch (eggs), DSMB, Anxiety disorder, GAD, Safety, Mental health, Quality of life, Unknown, Monash University, FDA, SBS, Clinical trial, Television, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that it has completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial, the Company’s Phase 2 study evaluating its own psilocybin treatment program for patients with generalized anxiety disorder (GAD).

Key Points: 
  • Independent documentary covering Monash Clinical Psychedelic Lab and PsiGAD research program to be released by SBS television network following 2 years of filming and production.
  • PsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial.
  • “Generalised anxiety disorder is characterised by persistent, debilitating and excessive worry, affects millions of people globally, and has inadequate existing treatment options.
  • An independent Data Safety Monitoring Board (DSMB) was tasked with confidentially reviewing the data for the first 37 out of 72 trial participants.